MET activation and Cetuximab resistance in patient-derived tumor xenografts

被引：0
|
作者：
Krumbach, Rebekka
Schuler, Julia
Hofmann, Michael
Fiebig, Heinz-Herbert
Beckers, Thomas
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-09-B74
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B74
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Signaling alterations in a collection of Cetuximab resistant and sensitive patient-derived tumor xenografts
    Krumbach, Rebekka
    Schueler, Julia
    Metz, Thomas
    Fiebig, Heinz Herbert
    Beckers, Thomas
    [J]. CANCER RESEARCH, 2009, 69
  • [2] Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance
    Krumbach, Rebekka
    Schueler, Julia
    Hofmann, Michael
    Giesemann, Torsten
    Fiebig, Heinz-Herbert
    Beckers, Thomas
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (08) : 1231 - 1243
  • [3] Generation of head and neck cancer patient-derived xenografts with in vivo acquired cetuximab resistance
    Zhou, Pei
    Li, Hua
    Wheeler, Sarah
    Grandis, Jennifer R.
    Stabile, Laura A.
    Egloff, Ann Marie
    [J]. CLINICAL CANCER RESEARCH, 2015, 21
  • [4] Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
    Xingxiang Pu
    Ran Zhang
    Li Wang
    Yungchang Chen
    Yi Xu
    Apar Pataer
    Ismail M. Meraz
    Xiaoshan Zhang
    Shuhong Wu
    Lin Wu
    Dan Su
    Weimin Mao
    John V. Heymach
    Jack A. Roth
    Stephen G. Swisher
    Bingliang Fang
    [J]. Journal of Translational Medicine, 16
  • [5] Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
    Pu, Xingxiang
    Zhang, Ran
    Wang, Li
    Chen, Yungchang
    Xu, Yi
    Pataer, Apar
    Meraz, Ismail M.
    Zhang, Xiaoshan
    Wu, Shuhong
    Wu, Lin
    Su, Dan
    Mao, Weimin
    Heymach, John V.
    Roth, Jack A.
    Swisher, Stephen G.
    Fang, Bingliang
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
  • [6] Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts
    Cassidy, John W.
    Caldas, Carlos
    Bruna, Alejandra
    [J]. CANCER RESEARCH, 2015, 75 (15) : 2963 - 2968
  • [7] Patient-Derived Tumor Xenografts Why Now?
    Liu, Edison T.
    Bult, Carol J.
    Shultz, Leonard D.
    [J]. JAMA ONCOLOGY, 2016, 2 (05) : 567 - 568
  • [8] Patient Characteristics Associated with Growth of Patient-Derived Tumor Implants in Mice (Patient-Derived Xenografts)
    Guerrero, Tatiana Hernandez
    Banos, Natalia
    Nevado, Laura del Puerto
    Mahillo-Fernandez, Ignacio
    De-Speville, Bernard Doger
    Calvo, Emiliano
    Wick, Michael
    Garcia-Foncillas, Jesus
    Moreno, Victor
    [J]. CANCERS, 2023, 15 (22)
  • [9] CHARACTERIZATION OF PATIENT-DERIVED TUMOR SPHERES AND XENOGRAFTS FOR GLIOBLASTOMA
    Kijima, Noriyuki
    Kanematsu, Daisuke
    Shofuda, Tomoko
    Yoshioka, Ema
    Handa, Yukako
    Moriuchi, Shusuke
    Nonaka, Masahiro
    Okita, Yoshiko
    Tsuyuguchi, Naohiro
    Fukai, Junya
    Higuchi, Yuichiro
    Suemizu, Hiroshi
    Kanemura, Yonehiro
    [J]. NEURO-ONCOLOGY, 2017, 19 : 258 - 258
  • [10] The future of patient-derived tumor xenografts in cancer treatment
    Sia, Daniela
    Moeini, Agrin
    Labgaa, Ismail
    Villanueva, Augusto
    [J]. PHARMACOGENOMICS, 2015, 16 (14) : 1671 - 1683
12345